180 related articles for article (PubMed ID: 34339834)
41. Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma.
Hiraga J; Kinoshita T; Ohno T; Mori N; Ohashi H; Fukami S; Noda A; Ichikawa A; Naoe T
Int J Hematol; 2006 Oct; 84(3):248-55. PubMed ID: 17050200
[TBL] [Abstract][Full Text] [Related]
42. [SOCSJ gene mutations in patients with diffuse large B-cell lymphoma].
Gavrilina OA; Zvonkov EE; Biderman BV; Severina NA; Parovichnikova EN
Ter Arkh; 2015; 87(7):105-111. PubMed ID: 26390734
[TBL] [Abstract][Full Text] [Related]
43. Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study.
Yamamoto M; Watanabe K; Fukuda T; Miura O
Anticancer Res; 2017 May; 37(5):2655-2662. PubMed ID: 28476841
[TBL] [Abstract][Full Text] [Related]
44. Diffuse large B cell lymphoma: from gene expression profiling to prediction of outcome.
Lossos IS
Biol Blood Marrow Transplant; 2008 Jan; 14(1 Suppl 1):108-11. PubMed ID: 18162230
[TBL] [Abstract][Full Text] [Related]
45. The significance of FOXP1 in diffuse large B-cell lymphoma.
Gascoyne DM; Banham AH
Leuk Lymphoma; 2017 May; 58(5):1037-1051. PubMed ID: 27678023
[TBL] [Abstract][Full Text] [Related]
46. Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma.
Camus V; Sarafan-Vasseur N; Bohers E; Dubois S; Mareschal S; Bertrand P; Viailly PJ; Ruminy P; Maingonnat C; Lemasle E; Stamatoullas A; Picquenot JM; Cornic M; Beaussire L; Bastard C; Frebourg T; Tilly H; Jardin F
Leuk Lymphoma; 2016 Sep; 57(9):2171-9. PubMed ID: 26883583
[TBL] [Abstract][Full Text] [Related]
47. Clinical efficacy and safety in relapsed/refractory diffuse large B-cell lymphoma: a systematic literature review.
Colosia A; Njue A; Trask PC; Olivares R; Khan S; Abbe A; Police R; Wang J; Ruiz-Soto R; Kaye JA; Awan F
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):343-355.e6. PubMed ID: 24768510
[TBL] [Abstract][Full Text] [Related]
48. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
Caimi PF; Ai W; Alderuccio JP; Ardeshna KM; Hamadani M; Hess B; Kahl BS; Radford J; Solh M; Stathis A; Zinzani PL; Havenith K; Feingold J; He S; Qin Y; Ungar D; Zhang X; Carlo-Stella C
Lancet Oncol; 2021 Jun; 22(6):790-800. PubMed ID: 33989558
[TBL] [Abstract][Full Text] [Related]
49. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
[TBL] [Abstract][Full Text] [Related]
50. [Genetic heterogeneity of DLBCL, not otherwise specified].
Karube K
Rinsho Ketsueki; 2017; 58(6):669-675. PubMed ID: 28680000
[TBL] [Abstract][Full Text] [Related]
51. [Clinical Application of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma--Review].
Chen XF; Wang M; Zhang F; Li JJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):638-642. PubMed ID: 33812444
[TBL] [Abstract][Full Text] [Related]
52. Non-Hodgkin's lymphoma: the old and the new.
Cabanillas F
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S87-90. PubMed ID: 22035756
[TBL] [Abstract][Full Text] [Related]
53. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma.
Young KH; Weisenburger DD; Dave BJ; Smith L; Sanger W; Iqbal J; Campo E; Delabie J; Gascoyne RD; Ott G; Rimsza L; Müller-Hermelink HK; Jaffe ES; Rosenwald A; Staudt LM; Chan WC; Greiner TC
Blood; 2007 Dec; 110(13):4396-405. PubMed ID: 17881637
[TBL] [Abstract][Full Text] [Related]
54. Prognostic mutation signature would serve as a potential prognostic predictor in patients with diffuse large B-cell lymphoma.
Cho SF; Yeh TJ; Wang HC; Du JS; Gau YC; Lin YY; Chuang TM; Liu YC; Hsiao HH; Moi SH
Sci Rep; 2024 Mar; 14(1):6161. PubMed ID: 38485750
[TBL] [Abstract][Full Text] [Related]
55. Characterization of the mutational profile of 11 diffuse large B-cell lymphoma cell lines.
Juskevicius D; Müller A; Hashwah H; Lundberg P; Tzankov A; Menter T
Leuk Lymphoma; 2018 Jul; 59(7):1710-1716. PubMed ID: 29043881
[TBL] [Abstract][Full Text] [Related]
56. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
57. p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas.
Leroy K; Haioun C; Lepage E; Le Métayer N; Berger F; Labouyrie E; Meignin V; Petit B; Bastard C; Salles G; Gisselbrecht C; Reyes F; Gaulard P;
Ann Oncol; 2002 Jul; 13(7):1108-15. PubMed ID: 12176791
[TBL] [Abstract][Full Text] [Related]
58. Clinical Effect of CD25 on the Prognosis of Diffuse Large B Cell Lymphoma with Secondary Central Nervous System Relapse.
Oka S; Ono K; Nohgawa M
Pathol Oncol Res; 2020 Jul; 26(3):1843-1850. PubMed ID: 31768966
[TBL] [Abstract][Full Text] [Related]
59. Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas.
Lossos IS; Okada CY; Tibshirani R; Warnke R; Vose JM; Greiner TC; Levy R
Blood; 2000 Mar; 95(5):1797-803. PubMed ID: 10688840
[TBL] [Abstract][Full Text] [Related]
60. Heterogeneity among diffuse large B-cell lymphoma: new entities in WHO classification, a first step in personalized therapy.
Rotaru I; Tănase AD; Nacea JG; Pătraşcu Ş; Olteanu OA; Pătraşcu AM
Rom J Morphol Embryol; 2019; 60(1):41-48. PubMed ID: 31263826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
